Navigation Links
Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government

NEW YORK, Feb. 26, 2009 /PRNewswire-FirstCall/ --Forest Laboratories, Inc. (NYSE: FRX) today announced that a complaint filed against the Company by the United States was unsealed in Massachusetts federal court alleging violations of the federal False Claims Act arising from Forest's marketing of its antidepressants Lexapro(R) and Celexa(R). The Complaint alleges that Forest personnel improperly promoted Lexapro and Celexa for off-label pediatric use, and that Forest paid kickbacks to physicians to induce them to prescribe these drugs. The Company understands that eleven states and the District of Columbia have also filed notices of intention to intervene as plaintiffs in the action. The Company had previously disclosed the government investigation in all periodic reports filed with the SEC since 2004. In its Form 10-Q filing for the period ending September 30, 2008, Forest disclosed the government's intention to assert civil claims against Forest under the False Claims Act. Forest is committed to adhering to the highest ethical and legal standards, and off-label promotion and improper payments to medical providers have consistently been against Forest policy. Forest is currently reviewing the complaint and will respond to this action at the appropriate time. In addition, as previously disclosed, Forest is continuing its discussions with the government about the investigation.

(Logo: )

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
2. Old-Growth Forests Dying Off in U.S. West
3. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
4. Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
5. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
6. Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
7. Forest Laboratories Responds To Unsolicited Mini-Tender Offer
8. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
9. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
10. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
11. Lake Forest, CA: SpeechPhone Launches Handsfree Driving Solution Just in Time to Comply with New Handsfree Driving Laws
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: